Regeneron Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Regeneron Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count).
Regeneron Pharmaceuticals: 280 sponsored US clinical trials, 61 recruiting.
Regeneron Pharmaceuticals sponsors 280 registered US clinical trials on ClinicalTrials.gov, 61 of them currently recruiting, and 151 completed. 83 of these trials are in Phase 3-4 (later-stage) and 174 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dermatitis, Atopic, with 6 trials.
Top-decile sponsor footprint
Regeneron Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
151 of 190 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
280 total, page 4 of 6
To Assess the Patients' Ability to Self-Administer Fasinumab
NCT03491904
Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe
NCT03767738
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT03738423
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT03736967
Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
NCT04173442
Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
NCT03691974
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
NCT03682770
Long Term Safety Study of PRALUENT
NCT03694197
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
NCT03633617
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
NCT03690869
REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
NCT03515629
Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT03580694
Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy
NCT03558997
Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
NCT03452228
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
NCT03430063
Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer
NCT03438318
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
NCT03409744
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
NCT03409614
A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva
NCT03188666
Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
NCT03399786
Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study
NCT03379558
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
NCT03346434
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
NCT03345914
Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
NCT03175367
Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
NCT03285646
Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
NCT03304379
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
NCT03156621
Study of Cemiplimab in Adults With Cervical Cancer
NCT03257267
A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
NCT03161093
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
NCT03132636
Study of REGN3500 and Dupilumab in Patients With Asthma
NCT03112577
Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers
NCT03146416
Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma
NCT03084640
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
NCT03054428
Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis
NCT03050151
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
NCT02744287
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
NCT03005782
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
NCT02957682
Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers
NCT02777151
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
NCT02680184
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
NCT02760498
Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects
NCT02828397
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
NCT02713204
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
NCT02718326
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
NCT02712008
Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects
NCT02741739
Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
NCT02683239
A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain
NCT02620020
Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
NCT02647086
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
NCT02325791
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 93 |
| Phase 2 | 81 |
| Phase 3 | 75 |
| Phase 4 | 8 |
What is open in the Regeneron Pharmaceuticals pipeline
61 recruiting of 280 indexed (22% open); 151 completed (54%).
Phase mix: 83 late (III/IV) vs 174 early (I/II) (early-phase heavy).
Top condition: Dermatitis, Atopic (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Regeneron Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 280 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
Regeneron Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 280 trials (± recruiting share)
- Boston Scientific Corporation · 280 trials · 8% recruiting
- Alcon Research · 275 trials · 2% recruiting
- Eisai · 287 trials · 2% recruiting
- SWOG Cancer Research Network · 270 trials · 10% recruiting
Sponsors near 22% open enrollment (± trial volume)
- AtriCure · 22% recruiting · 23 trials
- University of Colorado, Boulder · 22% recruiting · 69 trials
- University of Maryland, College Park · 22% recruiting · 46 trials
- Northwell Health · 22% recruiting · 370 trials
Related
What to do with this Regeneron Pharmaceuticals page
280 registered trials is a research-attention snapshot, not an endorsement of Regeneron Pharmaceuticals or any single study.
- 61 of Regeneron Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Dermatitis, Atopic is the condition Regeneron Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dermatitis, Atopic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Regeneron Pharmaceuticals pipeline card: 280 registered trials from official public datasets.Report a data error.